Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cyclerion Therapeutics, Inc. - Common Stock
(NQ:
CYCN
)
1.930
+0.130 (+7.22%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclerion Therapeutics, Inc. - Common Stock
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
January 06, 2026
Via
AB Newswire
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 05, 2026
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
September 23, 2025
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
December 17, 2024
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Regina Graul, Ph.D., Promoted to Chief Executive Officer
August 07, 2024
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Appoints Regina Graul, Ph.D., as President
December 04, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 30, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Reverse Stock Split
May 15, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 27, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 22, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
